Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glucocorticoid · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Abiraterone acetate | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Abiraterone acetate | DRUG | Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily |
| Glucocorticoid | DRUG | prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily |
Inclusion Criteria: * Completed 12 cycles of abiraterone acetate under study COU-AA-001 * Last dose of abiraterone acetate within 14 days prior to treatment in this study * Demonstrates potential to gain clinical benefit with continued abiraterone acetate treatment * Serum potassium level \>=3.5 mm...
Glucocorticoid is an investigational small molecule being studied for the treatment of prostate neoplasms, a type of cancer. It is currently in Phase 1 clinical development. The drug is being evaluated in patients with advanced prostate cancer who have completed a prior clinical study.
Glucocorticoid is being developed by Johnson & Johnson, a pharmaceutical company listed on the stock exchange under the ticker symbol JNJ. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with prostate neoplasms.
Glucocorticoid is in Phase 1 of clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for the treatment of prostate neoplasms, and its clinical trial has been completed.
Glucocorticoid has been studied in one clinical trial with the identifier NCT01664728. This was an expanded access study of abiraterone acetate in patients with advanced prostate cancer who had completed clinical study COU-AA-001. The trial was conducted in the United Kingdom and enrolled 54 male participants aged 18 years and older.
Glucocorticoid is not the same as abiraterone acetate. The clinical trial NCT01664728 was an expanded access study of abiraterone acetate, and Glucocorticoid is the drug being investigated in that study. The trial evaluated the drug in patients with advanced prostate cancer.